ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines

被引:33
作者
Tang, Ying [1 ]
Hou, Jingming [2 ]
Li, Guanghui [1 ]
Song, Zongchang [1 ]
Li, Xiaojing [1 ]
Yang, Cui [1 ]
Liu, Wenying [1 ]
Hu, Yide [1 ]
Xu, Yu [3 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400038, Peoples R China
[2] Chinese PLA Beijing Army Gen Hosp, Dept Orthoped, Beijing 100700, Peoples R China
[3] Third Mil Med Univ, Inst Resp Dis, Xinqiao Hosp, Chongqing 400038, Peoples R China
基金
中国国家自然科学基金;
关键词
ABCG2; drug resistance; NSCLC; symmetric division; asymmetric division; MULTIDRUG-RESISTANCE; STEM-CELLS; ASYMMETRIC DIVISION; DRUG-RESISTANCE; IN-VIVO; EXPRESSION; CHEMOTHERAPY; TRANSPORTER; SUPPRESSION; PHENOTYPE;
D O I
10.3892/or.2014.3470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of ABCG2 is considered a major mechanism of cancer drug resistance. Recent studies have shown that ABCG2 can regulate the switch between symmetric and asymmetric cell division in adult stem cells; however, the relationship between ABCG2 and cell division in drug-resistant cancer cells remains to be determined. In the present study, we demonstrated that ABCG2 is involved in the cell division of drug-resistant cancer cells. We first established drug-resistant H460 and A549 cell lines by repeated exposure to cisplatin and found that the expression of ABCG2 in these cell lines was significantly increased. As evidenced by PKH-26 staining, these drug-resistant cell lines favored symmetric division, which differed from the asymmetric division of the parental cells. Furthermore, we established stable ABCG2-overexpressing and stable shRNA-ABCG2-knock-down cell lines to evaluate the potential role of ABCG2 in cancer cell division. The results showed that overexpression of ABCG2 in A549 parental cells significantly increased the proportion of symmetric division, whereas knockdown of ABCG2 in drug-resistant A549 cells significantly increased the proportion of asymmetric division. Taken together, our findings suggest that ABCG2 is involved in the modulation of cancer drug resistance by regulating the pattern of cell division. The present study provides novel insight into the role of ABCG2 in cancer treatment resistance.
引用
收藏
页码:2168 / 2174
页数:7
相关论文
共 50 条
[31]   Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway [J].
Li, Yu ;
Yan, Hengyi ;
Xu, Xiaoman ;
Liu, Hongbo ;
Wu, Cen ;
Zhao, Li .
ONCOLOGY LETTERS, 2020, 19 (01) :323-333
[32]   Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer [J].
Okamura, Jun ;
Huang, Yiping ;
Moon, David ;
Brait, Mariana ;
Chang, Xiaofei ;
Kim, Myoung Sook .
CANCER BIOLOGY & THERAPY, 2012, 13 (03) :148-155
[33]   Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations [J].
Lopez-Ayllon, Blanca D. ;
Moncho-Amor, Veronica ;
Abarrategi, Ander ;
Ibanez de Caceres, Inmaculada ;
Castro-Carpeno, Javier ;
Belda-Iniesta, Cristobal ;
Perona, Rosario ;
Sastre, Leandro .
CANCER MEDICINE, 2014, 3 (05) :1099-1111
[34]   Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients [J].
Chen, Xueqin ;
Chen, Dadong ;
Yang, Shaoyu ;
Ma, Ruobing ;
Pan, Yuelong ;
Li, Xin ;
Ma, Shenglin .
CANCER CELL INTERNATIONAL, 2015, 15 :1
[35]   Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer [J].
Omori, Miwako ;
Noro, Rintaro ;
Seike, Masahiro ;
Matsuda, Kuniko ;
Hirao, Mariko ;
Fukuizumi, Aya ;
Takano, Natsuki ;
Miyanaga, Akihiko ;
Gemma, Akihiko .
THORACIC CANCER, 2022, 13 (15) :2142-2151
[36]   MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin [J].
Zhao, Han ;
Xie, Yu-Zhuo ;
Xing, Rui ;
Sun, Ming ;
Chi, Feng ;
Zeng, Yue-Can .
CELLULAR ONCOLOGY, 2017, 40 (04) :357-365
[37]   Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer [J].
Paul, I. ;
Chacko, A. D. ;
Stasik, I. ;
Busacca, S. ;
Crawford, N. ;
McCoy, F. ;
McTavish, N. ;
Wilson, B. ;
Barr, M. ;
O'Byrne, K. J. ;
Longley, D. B. ;
Fennell, D. A. .
CELL DEATH & DISEASE, 2012, 3 :e449-e449
[38]   FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells [J].
He, Yuwen ;
Xie, Hui ;
Yu, Pengjiu ;
Jiang, Shunjun ;
Wei, Li .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) :1049-1059
[39]   Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway [J].
Chen, Yun ;
Hong, Chaojin ;
Chen, Xiaochen ;
Qin, Zhiquan .
ONCOLOGY LETTERS, 2020, 20 (05)
[40]   Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment [J].
Yanyun Gao ;
Patrick Dorn ;
Shengchen Liu ;
Haibin Deng ;
Sean R. R. Hall ;
Ren-Wang Peng ;
Ralph A. Schmid ;
Thomas M. Marti .
Cancer Cell International, 19